NCT01298752

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

The Efficacy and Safety of Mapracorat Ophthalmic Suspension, 3% in Subjects for the Treatment of Ocular Inflammation Following Cataract Surgery

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 177 (actual)
• Sponsor: Bausch & Lomb Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.

Conditions

• Inflammation
• Pain
• Cataract

Interventions

Type	Name	Description
DRUG	Mapracorat	Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
DRUG	Vehicle	Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.

Timeline

• Start date: 2011-02-01
• Primary completion: 2011-09-01
• Completion: 2011-11-01
• First posted: 2011-02-18
• Last updated: 2020-09-03
• Results posted: 2020-09-03

Locations

1 site across 1 country: United States